EUVIMEDEUVIMED entdecken
Crossref

Randox’s new £400m testing deal explained, and why doctors are concerned

Elisabeth Mahase

BMJ · 18.11.2026 · 395 · e101499

DOI: 10.1136/bmj-2026-101499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMJ, online erschienen am 18.11.2026. Verfasst von Elisabeth Mahase. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The diagnostics company that faced heavy criticism in the covid pandemic has been handed a new multimillion pound deal by the government. Elisabeth Mahase examines the details

Zitieren

APA

Mahase, E. (2026). Randox’s new £400m testing deal explained, and why doctors are concerned. BMJ, 395, e101499. https://doi.org/10.1136/bmj-2026-101499

Vancouver

Mahase E. Randox’s new £400m testing deal explained, and why doctors are concerned. BMJ. 2026;395:e101499. doi:10.1136/bmj-2026-101499

BibTeX
@article{Mahase2026,
  author = {Mahase, Elisabeth},
  title = {Randox’s new £400m testing deal explained, and why doctors are concerned},
  journal = {BMJ},
  year = {2026},
  volume = {395},
  pages = {e101499},
  doi = {10.1136/bmj-2026-101499}
}
Kostenlos starten →